RGNX
Regenxbio Inc

2,917
Mkt Cap
$430.45M
Volume
791,864.00
52W High
$16.19
52W Low
$5.04
PE Ratio
-2.22
RGNX Fundamentals
Price
$8.34
Prev Close
$8.10
Open
$8.34
50D MA
$10.42
Beta
1.64
Avg. Volume
931,576.48
EPS (Annual)
-$3.76
P/B
4.13
Rev/Employee
$459,409.70
$773.10
Loading...
Loading...
News
all
press releases
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
REGENXBIO Inc. $RGNX Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. increased its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 4.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,037,248 shares of the biotechnology company's stock...
MarketBeat·2d ago
News Placeholder
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Zacks·4d ago
News Placeholder
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.
Zacks·4d ago
News Placeholder
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.
Zacks·4d ago
News Placeholder
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, March 19, 2026...
PR Newswire·4d ago
News Placeholder
REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action
Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and...
Business Wire·4d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX INVESTOR ALERT: Pomerantz Law Firm Reminds...
PR Newswire·5d ago
News Placeholder
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP PR...
PR Newswire·5d ago
News Placeholder
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP...
PR Newswire·6d ago
<
1
2
...
>

Latest RGNX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.